

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

Location: Cisco Webex, (408)418-9388  
Meeting ID: 1877 81 0095  
Password: AcckTBJQ223

**IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS**

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT [bochoa@alamedaalliance.org](mailto:bochoa@alamedaalliance.org). YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

**PLEASE NOTE:** THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

## AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> <li>Agenda Overview</li> </ul>	2 min	-
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Medical-RX</li> <li>DHCS-DMHC Joint Audits</li> <li>CalAim: ECM and ILOS, Major Organ Transplant</li> <li>BH</li> <li>COVID-19</li> </ul>	15 min	-
III)	<b>Pharmacy Utilization Reports (Quarter 1 2021)</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Top 50 Drugs by Cost</li> <li>Top 100 PA Reviewed Drugs</li> </ul>	2 min	-

**IV) E-Voting Material/Consent Agenda**

**The following items have been sent to the voting committee for review via E-voting**

*Rahel Negash, PharmD, Pharmacist, PerformRx*

*(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)*

Monographs/Class Reviews	Changes
Benzodiazepines	<ul style="list-style-type: none"> <li>Change flurazepam (Dalmane) 15, 30 mg capsule from F-QL (30/30) AL (64 yrs max) to F-QL (30/30)</li> <li>For Alprazolam MRG: remove neurology prescriber type</li> </ul>
Vasopressin antagonists	<ul style="list-style-type: none"> <li>No change</li> </ul>
Contraceptives, foams, devices	<ul style="list-style-type: none"> <li>No change</li> </ul>
Phosphate binders	<ul style="list-style-type: none"> <li>Change Auryxia and Velphoro tablet from NF to F-PA</li> <li>Note sevelamer (Renagel) and Lanthanum (Fosrenol) as preferred agents in PA criteria</li> <li>Remove “non-formulary” heading in medication section</li> <li>Remove extraneous word “tablets” in criteria</li> </ul>
Gaucher Disease	<ul style="list-style-type: none"> <li>No change</li> </ul>
Ridaura monograph	<ul style="list-style-type: none"> <li>No change</li> </ul>
Medication Request Guidelines	Changes
Specialty Biological Agents for Rheumatoid Arthritis	<ul style="list-style-type: none"> <li>Add Avsola to non-preferred medications</li> <li>Reorder bullet points for clarity</li> </ul>
Specialty Biological Agents for Ulcerative Colitis	<ul style="list-style-type: none"> <li>Add Avsola to non-preferred medications</li> </ul>
Specialty Biological Agents for Ankylosing Spondylitis	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Specialty Biological Agents for Giant Cell Arteritis	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Specialty Biological Agents for Uveitis	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations	<ul style="list-style-type: none"> <li>Add in Wixela Inhub name</li> </ul>
Fenofibrates	<ul style="list-style-type: none"> <li>Add gemfibrozil to formulary agents</li> </ul>
Serotonin Receptor Agonists (Triptans)	<ul style="list-style-type: none"> <li>Remove Sumavel (off market)</li> <li>Add authorized generic Zomig nasal spray to NF medications</li> </ul>
Ophthalmic Anti-inflammatory Immunomodulators	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Daliresp (roflumilast)	<ul style="list-style-type: none"> <li>Update the less than symbol to words</li> </ul>

10 min EV

Rapid-Acting Insulin	• Add Lyumjev under non-formulary products
Levalbuterol (Xopenex/Xopenex HFA)	• Add 1.25mg/0.5ml solution
Palforzia	• Remove extraneous “a” under the 3rd bullet point
Brand Medications When a Generic or Biosimilar is Available	• No changes
Formulary, step therapy required *For drugs without specific criteria	• No changes
Non-formulary and prior authorization required oral liquid formulations	• No changes
Potassium-removing agents	• No changes
Nutritional formulas, infant formulas	• No changes
febuxostat (Uloric)	• No changes
Modafinil and Armodafinil	• No changes
Rectiv (nitroglycerin) ointment	• No changes
<b>Interim Formulary changes</b>	
• See p. 134 in packet	
<b>Pharmacy Policy &amp; Procedure Updates</b>	
• RX003 Exception Review Process – <b>Changes:</b> OTC attestation for non-transitioning members	
• RX010 Drug Utilization Management – <b>Changes:</b> Update post Carve Out language	
• RX012 DU Policies: Pharmacy Portal & DU Access – <b>Changes:</b> Added section: “How To Use the MCP Pharmacy Portal” to address DHCS 13.B section #2 deliverable	
<b>90 Day Maintenance List</b>	
• Add Atrovent HFA, Spiriva Respimat and Stiolto Respimat, Hydroxychloroquine and Leflunomide	
• Reformat list structure	
<b>ED Oversight Updates</b>	
• No findings	
<b>P&amp;T Meeting Minutes</b>	
• P&T Meeting Minutes Q1 March 16, 2021	

**ADJOURN TO CLOSED SESSION** (Pursuant to California Government Code Title 5, §54954.5(h))

*Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes*  
*Estimated Date of Public Disclosure: 6/15/2021 (formulary changes only; no trade secrets will be disclosed).*

**V) New Business**

Natalee Felten, PharmD, Pharmacist, PerformRx

- **New MRG:** Vaginal Progesterone
- Physician Administered Drug (PAD) Medication Request Guideline Document

**New:**

- B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy (Abecma)
- Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis

45  
min

V

**Revise:**

- Complement inhibitors
- Anti-CD19 CAR-T Immunotherapies
- Prophylactic Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors for injection
- Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
- Spinraza
- Nagalzyme
- Specialty Biological Agents for Non-FDA Approved Medically Accepted Indications
- Specialty Biological Agents for Ankylosing Spondylitis
- Specialty Biological Agents for Crohn's Disease
- Specialty Biological Agents for Ulcerative Colitis
- Specialty Biological Agents for Rheumatoid Arthritis
- Specialty Biological Agents for Psoriatic Arthritis (PsA)
- Specialty Biological Agents for Psoriasis
- Specialty Biological Agents for Hidradenitis Suppurativa
- Specialty Biological Agents for Giant Cell Arteritis
- Specialty Biological Agents for Uveitis

**Retire:**

- Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis

**VI) Class Reviews, Monographs, and Recommendations**

*Natalee Felten, PharmD, Pharmacist, Perform*

- 
1. Cabenuva monograph
  2. Lupkynis monograph
  3. Verquvo monograph
  4. Qelbree monograph
  5. Hereditary Angioedema
  6. Anticonvulsants

**VII) Medication Request Guidelines**

*Rahel Negash, PharmD, Pharmacist, Alameda Alliance*

- 
1. Entresto
  2. Diabetes Medications and Diabetes Medications used for Heart Failure
  3. Long-Acting Basal Insulin
  4. Acute Migraine Treatments
  5. Self-administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
  6. Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
  7. Tranexamic acid (Lysteda)
  8. Lipotropics
  9. Prophylactic Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors for Injection
  10. Hepatitis C
  11. Hepatitis B drugs
  12. Hemlibra (emicizumab-kxwh)
  13. Movement Disorders
  14. Sunosi, Wakix, and Xyrem
  15. Lidocaine (Lidoderm)
-

16. Corlanor (ivabradine)
17. Emflaza (deflazacort)
18. Cholinesterase Inhibitors
19. Long Acting Opioids
20. Short Acting Opioids
21. Specialty Biological Agents for Non-Systemic Juvenile Idiopathic Arthritis

**VIII) Medication Request Guidelines (All below changes reflected in PAD criteria)**

*Rahel Negash, PharmD, Pharmacist, Alameda Alliance*

22. Specialty Biological Agents for Non-FDA Approved Medically Accepted Indications
23. Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis - *Retire*
24. Specialty Biological Agents for Crohn’s Disease
25. Specialty Biological Agents for Psoriatic Arthritis (PsA)
26. Specialty Biological Agents for Psoriasis
27. Specialty Biological Agents for Hidradenitis Suppurativa

**IX) Summary of Closed Session**

*Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance*

**RECONVENE IN OPEN SESSION**

ITEM	DESCRIPTION	TIME	VOTE
<b>X)</b>	<b>Informational Updates on New Developments in Pharmacy</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>	2 min	-
	<ul style="list-style-type: none"> <li>• New Product Review</li> </ul>		
<b>XI)</b>	<b>Old Business</b>	0 min	
	<ul style="list-style-type: none"> <li>• None</li> </ul>		
<b>XII)</b>	<b>Public Comment</b>	0 min	-
<b>XIII)</b>	<b>Adjournment</b>		
	<ul style="list-style-type: none"> <li>• P&amp;T Committee Member Forms</li> </ul>		

ACTION / FOLLOW-UP ITEMS		
ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
2021 P&T MEETINGS	
September 21st, 2021	December 21st, 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.